- +1-315-215-1633
- sales@thebrainyinsights.com
The global obstetrics and gynaecology drugs market was valued at USD 14.07 billion in 2022 and is anticipated to grow at a CAGR of 7.6% from 2022 to 2030. The global obstetrics and gynaecology drugs market is expected to reach USD 25.28 billion by 2030. Europe is expected to grow the fastest during the forecast period.
Gynaecology and Obstetrics encompass diverse medical conditions relating to women's reproductive systems. Women's lifestyle changes have led to increased obstetric and gynaecological disorders affecting the appendages, the uterus, and the ovaries. Several symptoms associated with gynecologic problems affect a female's reproductive system, including vaginal tingling and vaginal release. The COVID-19 outbreak has prompted the pharmaceutical industry into action, which has impacted the management of patients with obstetrics and gynaecology diseases due to a race for therapeutic and preventive drugs. In addition to treating cancers of the reproductive system, obstetrics and gynaecology drugs are also used to treat menstrual disorders, such as menorrhagia, cramping and pre-menstrual syndrome. Revenue growth of the obstetrics and gynaecology drugs market is driven by rising awareness regarding diagnosing and treating menstrual disorders and pregnancy-related infections. In recent years, acupuncture, Su Jok therapy, homoeopathy, and yoga have gained popularity and are slowly replacing some traditional hospital practices. Moreover, genetic sequencing and precision medicine are being combined by pharmaceutical companies to develop new cancer treatments and drug therapies. Additionally, a growing geriatric female population and revitalized economic growth are likely to contribute to the growth of obstetrics and gynaecology drugs. Continuous research and development are going on in the pharmaceutical industry to develop more efficient and innovative drugs with more healing effects and that can cover a wide spectrum of obstetrics and gynaecology diseases.
Get an overview of this study by requesting a free sample
Drivers:
Rising investments in R&D – All the companies which are dealing with healthcare products and services are investing a lot in the research and development sector of pharmaceutical manufacturing in order to develop more effective, stable and acceptable drugs for the treatment of obstetrics and gynaecology diseases. The increasing demand for drugs and quick approval by the government is prompting the market players to invest in the manufacturing of new drugs for obstetrics and gynaecology related diseases.
Restraints:
Disadvantages associated with hormonal therapy - A major reason for the slow growth of the market is the risk of breast cancer and other complications associated with hormonal therapy. Furthermore, there are several disadvantages of obstetrics and gynaecology, such as women might start having hormonal changes and mood swings, heavy or no bleeding, etc. This is expected to hinder the market’s growth.
Opportunities:
Rising awareness about healthy lifestyle – Gynecological treatments have increased in demand as consumers become more aware of nutrition, good health, and overall well-being. This is one of the major factors that will account for a large share of the market's growth in the upcoming years. Awareness programmes for women are being conducted to help them know about the circumstances of ignoring symptoms. These reasons provide growth opportunities for the market during the forecast period.
Challenges:
Rising alternative methods – Natural remedies and alternative treatment methods are becoming increasingly popular globally, which is expected to impact obstetrics and gynaecological drug manufacturers' revenues negatively. Furthermore, the treatments available in the fields of homoeopathy, Ayurveda, yoga, sujok therapy, and acupuncture are gaining popularity and slowly replacing some traditional hospital practices, which challenges the market’s growth over the forecast period.
Regional segmentation analysis:
The regions analyzed for the market include North America, Europe, South America, Asia Pacific, the Middle East, and Africa. North America emerged as the largest market for the global obstetrics and gynaecology drugs market, with a 36.92% share of the market revenue in 2022. Post-partum conditions, polycystic ovary syndrome, and childbirth are all contributing factors to the rise of obstetrics and gynaecology drug demand in the region which are propelling the growth of the obstetrics and gynaecology drugs market. For instance, according to a report released in May 2022 by the Canadian Cancer Society, it is predicted that in 2022, about 1,450 Canadian women will be diagnosed with cervical cancer, and approximately 380 of them will pass away from the disease.
Europe is expected to be the fastest-growing region. Significant factors drive market growth in Europe, including a growing awareness of various gynaecological illnesses and their long-term effects among females. Furthermore, the increasing cases of ovarian cancer among women also add to the market's growth in the region
North America Region Obstetrics and Gynaecology Drugs Market Share in 2022 - 36.92%
www.thebrainyinsights.com
Check the geographical analysis of this market by requesting a free sample
Type segment analysis
The type segment is divided into non-hormonal therapy and hormonal therapy. The non-hormonal therapy segment dominated, with a market share of around 55.35% in 2022. The market has been growing owing to their proven efficiency in treating diseases, rapid advancements in new product development with reduced side effects, availability in a wide range of markets, and the increasing popularity of these products.
Application segment analysis
The application segment is divided into female infertility, contraception, postmenopausal disorders, gynaecology infections, endometriosis, and others. Over the forecast period, the gynaecology infections segment is expected to grow at the fastest CAGR of 8.6%. Hormone therapy for gynaecology infections, also known as hormone replacement therapy, is recommended to stop the growth of the cancer cells treatment and biological changes caused by the declining levels of estrogen and progesterone in a woman's body.
Distribution channel segment analysis
The distribution channel segment is divided into online pharmacies, hospital pharmacies, and retail pharmacies. The hospital pharmacies segment dominated, with a market share of around 38.3% in 2022. Most of obstetrics and gynaecology drugs are prescribed by doctors after the proper diagnosis of the disease. So, the patients tend to purchase the drugs from hospital pharmacies, propelling the segment’s growth.
Report Description:
| Attribute | Description |
|---|---|
| Market Size | Revenue (USD Billion) |
| Market size value in 2022 | USD 14.07 Billion |
| Market size value in 2030 | USD 25.28 Billion |
| CAGR (2022 to 2030) | 7.6% |
| Historical data | 2019-2020 |
| Base Year | 2021 |
| Forecast | 2022-2030 |
| Segments | Type, Application, Distribution Channel |
| Regional Segments | North America, Asia Pacific, Europe, Latin America, Middle East and Africa |
As per The Brainy Insights, the size of the obstetrics and gynaecology drugs market was valued at USD 14.07 billion in 2022 to USD 25.28 billion by 2030.
The global obstetrics and gynaecology drugs market is growing at a CAGR of 7.6% during the forecast period 2022-2030.
North America emerged as the largest market for obstetrics and gynaecology drugs.
Key players in the obstetrics and gynaecology drugs market are Lupin Limited, Bayer AG, Pfizer, Inc, Eli Lily and Company, Ltd., AbbVie, Inc., Ferring B.V., Johnson & Johnson, AstraZeneca, Merck & Co., Inc., Hoffman-La Roche, Ltd.
1. Introduction
1.1. Objectives of the Study
1.2. Market Definition
1.3. Research Scope
1.4. Currency
1.5. Key Target Audience
2. Research Methodology and Assumptions
3. Executive Summary
4. Premium Insights
4.1. Porter’s Five Forces Analysis
4.2. Value Chain Analysis
4.3. Top Investment Pockets
4.3.1. Market Attractiveness Analysis By Type
4.3.2. Market Attractiveness Analysis By Application
4.3.3. Market Attractiveness Analysis By Distribution Channel
4.3.4. Market Attractiveness Analysis By Region
4.4. Industry Trends
5. Market Dynamics
5.1. Market Evaluation
5.2. Drivers
5.2.1. Rising investments in R&D
5.3. Restraints
5.3.1. Disadvantages associated with hormonal therapy
5.4. Opportunities
5.4.1. Rising awareness about healthy lifestyle
5.5. Challenges
5.5.1. Rising alternative methods
1. Global Obstetrics and Gynaecology Drugs Market Analysis and Forecast, By Type
1.1. Segment Overview
1.2. Non-Hormonal Therapy
1.3. Hormonal Therapy
2. Global Obstetrics and Gynaecology Drugs Market Analysis and Forecast, By Application
2.1. Segment Overview
2.2. Female Infertility
2.3. Contraception
2.4. Postmenopausal Disorders
2.5. Gynaecology Infections,
2.6. Endometriosis
2.7. Others
3. Global Obstetrics and Gynaecology Drugs Market Analysis and Forecast, By Distribution Channel
3.1. Segment Overview
3.2. Online Pharmacies
3.3. Hospital Pharmacies
3.4. Retail Pharmacies
4. Global Obstetrics and Gynaecology Drugs Market Analysis and Forecast, By Regional Analysis
4.1. Segment Overview
4.2. North America
4.2.1. U.S.
4.2.2. Canada
4.2.3. Mexico
4.3. Europe
4.3.1. Germany
4.3.2. France
4.3.3. U.K.
4.3.4. Italy
4.3.5. Spain
4.4. Asia-Pacific
4.4.1. Japan
4.4.2. China
4.4.3. India
4.5. South America
4.5.1. Brazil
4.6. Middle East and Africa
4.6.1. UAE
4.6.2. South Africa
5. Global Obstetrics and Gynaecology Drugs Market-Competitive Landscape
5.1. Overview
5.2. Market Share of Key Players in Global Obstetrics and Gynaecology Drugs Market
5.2.1. Global Company Market Share
5.2.2. North America Company Market Share
5.2.3. Europe Company Market Share
5.2.4. APAC Company Market Share
5.3. Competitive Situations and Trends
5.3.1. Product Launches and Developments
5.3.2. Partnerships, Collaborations, and Agreements
5.3.3. Mergers & Acquisitions
5.3.4. Expansions
6. Company Profiles
6.1. Lupin Limited
6.1.1. Business Overview
6.1.2. Company Snapshot
6.1.3. Company Market Share Analysis
6.1.4. Company Product Portfolio
6.1.5. Recent Developments
6.1.6. SWOT Analysis
6.2. Bayer AG
6.2.1. Business Overview
6.2.2. Company Snapshot
6.2.3. Company Market Share Analysis
6.2.4. Company Product Portfolio
6.2.5. Recent Developments
6.2.6. SWOT Analysis
6.3. Pfizer, Inc
6.3.1. Business Overview
6.3.2. Company Snapshot
6.3.3. Company Market Share Analysis
6.3.4. Company Product Portfolio
6.3.5. Recent Developments
6.3.6. SWOT Analysis
6.4. Eli Lily and Company, Ltd.
6.4.1. Business Overview
6.4.2. Company Snapshot
6.4.3. Company Market Share Analysis
6.4.4. Company Product Portfolio
6.4.5. Recent Developments
6.4.6. SWOT Analysis
6.5. AbbVie, Inc.
6.5.1. Business Overview
6.5.2. Company Snapshot
6.5.3. Company Market Share Analysis
6.5.4. Company Product Portfolio
6.5.5. Recent Developments
6.5.6. SWOT Analysis
6.6. Ferring B.V.
6.6.1. Business Overview
6.6.2. Company Snapshot
6.6.3. Company Market Share Analysis
6.6.4. Company Product Portfolio
6.6.5. Recent Developments
6.6.6. SWOT Analysis
6.7. Johnson & Johnson
6.7.1. Business Overview
6.7.2. Company Snapshot
6.7.3. Company Market Share Analysis
6.7.4. Company Product Portfolio
6.7.5. Recent Developments
6.7.6. SWOT Analysis
6.8. AstraZeneca
6.8.1. Business Overview
6.8.2. Company Snapshot
6.8.3. Company Market Share Analysis
6.8.4. Company Product Portfolio
6.8.5. Recent Developments
6.8.6. SWOT Analysis
6.9. Merck & Co., Inc.
6.9.1. Business Overview
6.9.2. Company Snapshot
6.9.3. Company Market Share Analysis
6.9.4. Company Product Portfolio
6.9.5. Recent Developments
6.9.6. SWOT Analysis
6.10. Hoffman-La Roche, Ltd.
6.10.1. Business Overview
6.10.2. Company Snapshot
6.10.3. Company Market Share Analysis
6.10.4. Company Product Portfolio
6.10.5. Recent Developments
6.10.6. SWOT Analysis
6.11. GlaxoSmithKline plc
6.11.1. Business Overview
6.11.2. Company Snapshot
6.11.3. Company Market Share Analysis
6.11.4. Company Product Portfolio
6.11.5. Recent Developments
6.11.6. SWOT Analysis
6.12. Abbott
6.12.1. Business Overview
6.12.2. Company Snapshot
6.12.3. Company Market Share Analysis
6.12.4. Company Product Portfolio
6.12.5. Recent Developments
6.12.6. SWOT Analysis
6.13. Novartis AG
6.13.1. Business Overview
6.13.2. Company Snapshot
6.13.3. Company Market Share Analysis
6.13.4. Company Product Portfolio
6.13.5. Recent Developments
6.13.6. SWOT Analysis
6.14. Amgen, Inc.
6.14.1. Business Overview
6.14.2. Company Snapshot
6.14.3. Company Market Share Analysis
6.14.4. Company Product Portfolio
6.14.5. Recent Developments
6.14.6. SWOT Analysis
List of Table
1. Global Obstetrics and Gynaecology Drugs Market, By Type, 2019-2030 (USD Billion)
2. Global Non-Hormonal Therapy, Obstetrics and Gynaecology Drugs Market, By Region, 2019-2030 (USD Billion)
3. Global Hormonal Therapy, Obstetrics and Gynaecology Drugs Market, By Region, 2019-2030 (USD Billion)
4. Global Obstetrics and Gynaecology Drugs Market, By Application, 2019-2030 (USD Billion)
5. Global Female Infertility, Obstetrics and Gynaecology Drugs Market, By Region, 2019-2030 (USD Billion)
6. Global Contraception, Obstetrics and Gynaecology Drugs Market, By Region, 2019-2030 (USD Billion)
7. Global Postmenopausal Disorders, Obstetrics and Gynaecology Drugs Market, By Region, 2019-2030 (USD Billion)
8. Global Gynaecology Infections, Obstetrics and Gynaecology Drugs Market, By Region, 2019-2030 (USD Billion)
9. Global Endometriosis, Obstetrics and Gynaecology Drugs Market, By Region, 2019-2030 (USD Billion)
10. Global Others, Obstetrics and Gynaecology Drugs Market, By Region, 2019-2030 (USD Billion)
11. Global Obstetrics and Gynaecology Drugs Market, By Distribution Channel, 2019-2030 (USD Billion)
12. Global Online Pharmacies, Obstetrics and Gynaecology Drugs Market, By Region, 2019-2030 (USD Billion)
13. Global Hospital Pharmacies, Obstetrics and Gynaecology Drugs Market, By Region, 2019-2030 (USD Billion)
14. Global Retail Pharmacies, Obstetrics and Gynaecology Drugs Market, By Region, 2019-2030 (USD Billion)
15. North America Obstetrics and Gynaecology Drugs Market, By Type, 2019-2030 (USD Billion)
16. North America Obstetrics and Gynaecology Drugs Market, By Application, 2019-2030 (USD Billion)
17. North America Obstetrics and Gynaecology Drugs Market, By Distribution Channel, 2019-2030 (USD Billion)
18. U.S. Obstetrics and Gynaecology Drugs Market, By Type, 2019-2030 (USD Billion)
19. U.S. Obstetrics and Gynaecology Drugs Market, By Application, 2019-2030 (USD Billion)
20. U.S. Obstetrics and Gynaecology Drugs Market, By Distribution Channel, 2019-2030 (USD Billion)
21. Canada Obstetrics and Gynaecology Drugs Market, By Type, 2019-2030 (USD Billion)
22. Canada Obstetrics and Gynaecology Drugs Market, By Application, 2019-2030 (USD Billion)
23. Canada Obstetrics and Gynaecology Drugs Market, By Distribution Channel, 2019-2030 (USD Billion)
24. Mexico Obstetrics and Gynaecology Drugs Market, By Type, 2019-2030 (USD Billion)
25. Mexico Obstetrics and Gynaecology Drugs Market, By Application, 2019-2030 (USD Billion)
26. Mexico Obstetrics and Gynaecology Drugs Market, By Distribution Channel, 2019-2030 (USD Billion)
27. Europe Obstetrics and Gynaecology Drugs Market, By Type, 2019-2030 (USD Billion)
28. Europe Obstetrics and Gynaecology Drugs Market, By Application, 2019-2030 (USD Billion)
29. Europe Obstetrics and Gynaecology Drugs Market, By Distribution Channel, 2019-2030 (USD Billion)
30. Germany Obstetrics and Gynaecology Drugs Market, By Type, 2019-2030 (USD Billion)
31. Germany Obstetrics and Gynaecology Drugs Market, By Application, 2019-2030 (USD Billion)
32. Germany Obstetrics and Gynaecology Drugs Market, By Distribution Channel, 2019-2030 (USD Billion)
33. France Obstetrics and Gynaecology Drugs Market, By Type, 2019-2030 (USD Billion)
34. France Obstetrics and Gynaecology Drugs Market, By Application, 2019-2030 (USD Billion)
35. France Obstetrics and Gynaecology Drugs Market, By Distribution Channel, 2019-2030 (USD Billion)
36. U.K. Obstetrics and Gynaecology Drugs Market, By Type, 2019-2030 (USD Billion)
37. U.K. Obstetrics and Gynaecology Drugs Market, By Application, 2019-2030 (USD Billion)
38. U.K. Obstetrics and Gynaecology Drugs Market, By Distribution Channel, 2019-2030 (USD Billion)
39. Italy Obstetrics and Gynaecology Drugs Market, By Type, 2019-2030 (USD Billion)
40. Italy Obstetrics and Gynaecology Drugs Market, By Application, 2019-2030 (USD Billion)
41. Italy Obstetrics and Gynaecology Drugs Market, By Distribution Channel, 2019-2030 (USD Billion)
42. Spain Obstetrics and Gynaecology Drugs Market, By Type, 2019-2030 (USD Billion)
43. Spain Obstetrics and Gynaecology Drugs Market, By Application, 2019-2030 (USD Billion)
44. Spain Obstetrics and Gynaecology Drugs Market, By Distribution Channel, 2019-2030 (USD Billion)
45. Asia Pacific Obstetrics and Gynaecology Drugs Market, By Type, 2019-2030 (USD Billion)
46. Asia Pacific Obstetrics and Gynaecology Drugs Market, By Application, 2019-2030 (USD Billion)
47. Asia Pacific Obstetrics and Gynaecology Drugs Market, By Distribution Channel, 2019-2030 (USD Billion)
48. Japan Obstetrics and Gynaecology Drugs Market, By Type, 2019-2030 (USD Billion)
49. Japan Obstetrics and Gynaecology Drugs Market, By Application, 2019-2030 (USD Billion)
50. Japan Obstetrics and Gynaecology Drugs Market, By Distribution Channel, 2019-2030 (USD Billion)
51. China Obstetrics and Gynaecology Drugs Market, By Type, 2019-2030 (USD Billion)
52. China Obstetrics and Gynaecology Drugs Market, By Application, 2019-2030 (USD Billion)
53. China Obstetrics and Gynaecology Drugs Market, By Distribution Channel, 2019-2030 (USD Billion)
54. India Obstetrics and Gynaecology Drugs Market, By Type, 2019-2030 (USD Billion)
55. India Obstetrics and Gynaecology Drugs Market, By Application, 2019-2030 (USD Billion)
56. India Obstetrics and Gynaecology Drugs Market, By Distribution Channel, 2019-2030 (USD Billion)
57. South America Obstetrics and Gynaecology Drugs Market, By Type, 2019-2030 (USD Billion)
58. South America Obstetrics and Gynaecology Drugs Market, By Application, 2019-2030 (USD Billion)
59. South America Obstetrics and Gynaecology Drugs Market, By Distribution Channel, 2019-2030 (USD Billion)
60. Brazil Obstetrics and Gynaecology Drugs Market, By Type, 2019-2030 (USD Billion)
61. Brazil Obstetrics and Gynaecology Drugs Market, By Application, 2019-2030 (USD Billion)
62. Brazil Obstetrics and Gynaecology Drugs Market, By Distribution Channel, 2019-2030 (USD Billion)
63. Middle East and Africa Obstetrics and Gynaecology Drugs Market, By Type, 2019-2030 (USD Billion)
64. Middle East and Africa Obstetrics and Gynaecology Drugs Market, By Application, 2019-2030 (USD Billion)
65. Middle East and Africa Obstetrics and Gynaecology Drugs Market, By Distribution Channel, 2019-2030 (USD Billion)
66. UAE Obstetrics and Gynaecology Drugs Market, By Type, 2019-2030 (USD Billion)
67. UAE Obstetrics and Gynaecology Drugs Market, By Application, 2019-2030 (USD Billion)
68. UAE Obstetrics and Gynaecology Drugs Market, By Distribution Channel, 2019-2030 (USD Billion)
69. South Africa Obstetrics and Gynaecology Drugs Market, By Type, 2019-2030 (USD Billion)
70. South Africa Obstetrics and Gynaecology Drugs Market, By Application, 2019-2030 (USD Billion)
71. South Africa Obstetrics and Gynaecology Drugs Market, By Distribution Channel, 2019-2030 (USD Billion)
List of Figures
1. Global Obstetrics and Gynaecology Drugs Market Segmentation
2. Global Obstetrics and Gynaecology Drugs Market: Research Methodology
3. Market Size Estimation Methodology: Bottom-Up Approach
4. Market Size Estimation Methodology: Top-Down Approach
5. Data Triangulation
6. Porter’s Five Forces Analysis
7. Value Chain Analysis
8. Global Obstetrics and Gynaecology Drugs Market Attractiveness Analysis By Type
9. Global Obstetrics and Gynaecology Drugs Market Attractiveness Analysis By Application
10. Global Obstetrics and Gynaecology Drugs Market Attractiveness Analysis By Distribution Channel
11. Global Obstetrics and Gynaecology Drugs Market Attractiveness Analysis By Region
12. Global Obstetrics and Gynaecology Drugs Market: Dynamics
13. Global Obstetrics and Gynaecology Drugs Market Share By Type (2022 & 2030)
14. Global Obstetrics and Gynaecology Drugs Market Share By Application (2022 & 2030)
15. Global Obstetrics and Gynaecology Drugs Market Share By Distribution Channel (2022 & 2030)
16. Global Obstetrics and Gynaecology Drugs Market Share By Regions (2022 & 2030)
17. Global Obstetrics and Gynaecology Drugs Market Share By Company (2021)
This study forecasts global, regional, and country revenue from 2019 to 2030. Brainy Insights has segmented the global obstetrics and gynaecology drugs market based on the below-mentioned segments:
Global Obstetrics and Gynaecology Drugs Market by Type:
Global Obstetrics and Gynaecology Drugs Market by Application:
Global Obstetrics and Gynaecology Drugs Market by Distribution Channel:
Global Obstetrics and Gynaecology Drugs Market by Region:
Research has its special purpose to undertake marketing efficiently. In this competitive scenario, businesses need information across all industry verticals; the information about customer wants, market demand, competition, industry trends, distribution channels etc. This information needs to be updated regularly because businesses operate in a dynamic environment. Our organization, The Brainy Insights incorporates scientific and systematic research procedures in order to get proper market insights and industry analysis for overall business success. The analysis consists of studying the market from a miniscule level wherein we implement statistical tools which helps us in examining the data with accuracy and precision.
Our research reports feature both; quantitative and qualitative aspects for any market. Qualitative information for any market research process are fundamental because they reveal the customer needs and wants, usage and consumption for any product/service related to a specific industry. This in turn aids the marketers/investors in knowing certain perceptions of the customers. Qualitative research can enlighten about the different product concepts and designs along with unique service offering that in turn, helps define marketing problems and generate opportunities. On the other hand, quantitative research engages with the data collection process through interviews, e-mail interactions, surveys and pilot studies. Quantitative aspects for the market research are useful to validate the hypotheses generated during qualitative research method, explore empirical patterns in the data with the help of statistical tools, and finally make the market estimations.
The Brainy Insights offers comprehensive research and analysis, based on a wide assortment of factual insights gained through interviews with CXOs and global experts and secondary data from reliable sources. Our analysts and industry specialist assume vital roles in building up statistical tools and analysis models, which are used to analyse the data and arrive at accurate insights with exceedingly informative research discoveries. The data provided by our organization have proven precious to a diverse range of companies, facilitating them to address issues such as determining which products/services are the most appealing, whether or not customers use the product in the manner anticipated, the purchasing intentions of the market and many others.
Our research methodology encompasses an idyllic combination of primary and secondary initiatives. Key phases involved in this process are listed below:
The phase involves the gathering and collecting of market data and its related information with the help of different sources & research procedures.
The data procurement stage involves in data gathering and collecting through various data sources.
This stage involves in extensive research. These data sources includes:
Purchased Database: Purchased databases play a crucial role in estimating the market sizes irrespective of the domain. Our purchased database includes:
Primary Research: The Brainy Insights interacts with leading companies and experts of the concerned domain to develop the analyst team’s market understanding and expertise. It improves and substantiates every single data presented in the market reports. Primary research mainly involves in telephonic interviews, E-mail interactions and face-to-face interviews with the raw material providers, manufacturers/producers, distributors, & independent consultants. The interviews that we conduct provides valuable data on market size and industry growth trends prevailing in the market. Our organization also conducts surveys with the various industry experts in order to gain overall insights of the industry/market. For instance, in healthcare industry we conduct surveys with the pharmacists, doctors, surgeons and nurses in order to gain insights and key information of a medical product/device/equipment which the customers are going to usage. Surveys are conducted in the form of questionnaire designed by our own analyst team. Surveys plays an important role in primary research because surveys helps us to identify the key target audiences of the market. Additionally, surveys helps to identify the key target audience engaged with the market. Our survey team conducts the survey by targeting the key audience, thus gaining insights from them. Based on the perspectives of the customers, this information is utilized to formulate market strategies. Moreover, market surveys helps us to understand the current competitive situation of the industry. To be precise, our survey process typically involve with the 360 analysis of the market. This analytical process begins by identifying the prospective customers for a product or service related to the market/industry to obtain data on how a product/service could fit into customers’ lives.
Secondary Research: The secondary data sources includes information published by the on-profit organizations such as World bank, WHO, company fillings, investor presentations, annual reports, national government documents, statistical databases, blogs, articles, white papers and others. From the annual report, we analyse a company’s revenue to understand the key segment and market share of that organization in a particular region. We analyse the company websites and adopt the product mapping technique which is important for deriving the segment revenue. In the product mapping method, we select and categorize the products offered by the companies catering to domain specific market, deduce the product revenue for each of the companies so as to get overall estimation of the market size. We also source data and analyses trends based on information received from supply side and demand side intermediaries in the value chain. The supply side denotes the data gathered from supplier, distributor, wholesaler and the demand side illustrates the data gathered from the end customers for respective market domain.
The supply side for a domain specific market is analysed by:
The demand side for the market is estimated through:
In-house Library: Apart from these third-party sources, we have our in-house library of qualitative and quantitative information. Our in-house database includes market data for various industry and domains. These data are updated on regular basis as per the changing market scenario. Our library includes, historic databases, internal audit reports and archives.
Sometimes there are instances where there is no metadata or raw data available for any domain specific market. For those cases, we use our expertise to forecast and estimate the market size in order to generate comprehensive data sets. Our analyst team adopt a robust research technique in order to produce the estimates:
Data Synthesis: This stage involves the analysis & mapping of all the information obtained from the previous step. It also involves in scrutinizing the data for any discrepancy observed while data gathering related to the market. The data is collected with consideration to the heterogeneity of sources. Robust scientific techniques are in place for synthesizing disparate data sets and provide the essential contextual information that can orient market strategies. The Brainy Insights has extensive experience in data synthesis where the data passes through various stages:
Market Deduction & Formulation: The final stage comprises of assigning data points at appropriate market spaces so as to deduce feasible conclusions. Analyst perspective & subject matter expert based holistic form of market sizing coupled with industry analysis also plays a crucial role in this stage.
This stage involves in finalization of the market size and numbers that we have collected from data integration step. With data interpolation, it is made sure that there is no gap in the market data. Successful trend analysis is done by our analysts using extrapolation techniques, which provide the best possible forecasts for the market.
Data Validation & Market Feedback: Validation is the most important step in the process. Validation & re-validation via an intricately designed process helps us finalize data-points to be used for final calculations.
The Brainy Insights interacts with leading companies and experts of the concerned domain to develop the analyst team’s market understanding and expertise. It improves and substantiates every single data presented in the market reports. The data validation interview and discussion panels are typically composed of the most experienced industry members. The participants include, however, are not limited to:
Moreover, we always validate our data and findings through primary respondents from all the major regions we are working on.
Free Customization
Fortune 500 Clients
Free Yearly Update On Purchase Of Multi/Corporate License
Companies Served Till Date
